key: cord-0708254-vt8se423
authors: Mutnal, Manohar B.; Mohammad, Amin A.; Arroliga, Alejandro C.; Hua, Yinan; Wang, Liping; Koss, William; Rao, Arundhati
title: Role of Anti-SARS-CoV-2 antibodies in different cohorts: Can they provide clues for appropriate patient triaging?
date: 2020-06-29
journal: bioRxiv
DOI: 10.1101/2020.06.26.174672
sha: 3ced552fa810131e67ab678366d53403b6d7e637
doc_id: 708254
cord_uid: vt8se423

The emergence of coronavirus disease 2019 (COVID-19) has become a major global health crisis. Currently, diagnosis is based on molecular techniques, which detect the viral nucleic acids when present at detectable levels. The serum IgG response against SARS-CoV-2 was examined by using an ELISA-based assay. Serum samples, along with nasopharyngeal specimens were collected from various cohorts and analyzed by ELISA and rRT-PCR, respectively. A total of 167 serum samples were tested for serum IgG antibodies against SARS-CoV-2 in outpatient cohorts, 15 (8.9%) were positive by rRT-PCR and the remaining 152 (91%) were negative. We used these data to generate two different assay cutoffs for serum IgG assay and investigated percent concordance with rRT-PCR test results. The emergency department data revealed, out of 151 nasopharyngeal swabs, 4 (2.6%) were positive by rRT-PCR and 18 (11.9%) were positive for serum IgG assay. Among the 18 patients that were positive for serum IgG, 13 (72.2%) exhibited 1-3 symptoms of COVID-19 and 5 (27.7%) patients did not present with any COVID-19 related symptoms, per CDC criteria. All 4 (100%) patients that were positive by rRT-PCR had symptoms of COVID-19 disease. A longitudinal study from the inpatient population suggested there was a sharp increase in the serum IgG titers in 5 patients, a moderate increase in 1 patient and a plateau in 3 patients. Sero-prevalence of COVID-19 disease in pre-procedure patients was 5.5%. Our findings suggest serological tests can be used for appropriate patient triaging when performed as an adjunct to existing molecular testing.

Nasopharyngeal and serum samples were concurrently collected from 151 patients who 110 visited the ED with suspected symptoms of SARS-CoV-2 infection. Specimens were collected 111 from patients who exhibited at least one symptom related to COVID-19 disease as indicated by 112 CDC. Symptoms included, fever, chills, cough, shortness of breath or difficulty breathing, 113 fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or 114 runny nose, nausea or vomiting, and diarrhea. 115 Inpatient specimens: 116 Several ED patients were transitioned to inpatient status due to clinical necessity. 117 Residual serum specimens from 9 SARS-CoV-2 confirmed inpatients were collected over a 118 period of their stay in the hospital and analyzed for serum IgG. One hundred pre-COVID-19 serum samples were selected from the BSWH specimen 128 biobank for specificity testing of the serum IgG assay. These specimens were collected during The SARS-CoV-2 primers were designed by Luminex to detect RNA targets from the 151 SARS-CoV-2 in respiratory specimens from patients, as recommended for testing by public implementation. In this study, we used 100 pre COVID-19 specimens for additional specificity 181 testing.

Sample dilution experiment 183 In order to rule out non-specific binding, specimens that tested positive by ELISA assay 184 were diluted using sample diluent provided in the assay kit. Specimens were diluted 1:2, 1:4, 1:8 185 and 1:16 and were re-tested along with an undiluted specimen. Percent recovery was calculated 186 and plotted.

189 Outpatient serological testing experience and test performance: 190 A total of 167 serum samples were tested for serum IgG antibodies against SARS-CoV-2; 191 15 (8.9%) were positive by rRT-PCR and the remaining 152 (91%) were negative. We used 192 these data to generate two different assay cutoffs for serum IgG and investigated the percent (Tables 1A and 1B) . Fig. 3 show that there was a moderate to high increase in the serum IgG titers for a few patients 236 within a very short period. Among the 9 patients that were followed, 5 demonstrated a sharp 237 increase in the IgG titers within 1-3 days of initial testing (patient numbers 1, 2, 4, 6 and 7).

There was moderate increase in the IgG titers for one patient (patient number 5) while the IgG Pre-procedure serological testing experience: 246 As mentioned in the methods, a total of 6,271 rRT-PCR and serum IgG tests were 247 performed by the end of June 12, 2020. Among the 6,271 rRT -PCR tests, 60 (0.95%) were 248 positive. Serum IgG test was positive for 351 (5.5%) patients among the patients who submitted 249 paired specimens for pre-procedure screening. Since the pre-procedure patient population represented a random group from various parts of the central Texas region, we estimated sero-251 prevalence of COVID-19 to be at 5.5% in this part of the nation.

Pre-procedure serological testing data clearly suggested a higher prevalence of COVID- performance data 14 . 263 We described the use of serological testing for SARS-CoV-2 infection in various 264 healthcare contexts, examining outpatient, emergency department, inpatient, and pre-procedure 265 patients. Outpatient data were utilized to determine the performance characteristics of the IgG 266 ELISA assay, which was validated and implemented as a laboratory-developed test. Two assay 267 cutoffs were established based on its performance compared to rRT-PCR method. Both the 268 cutoffs provided a nearly 100% negative predictive value.

As shown by many studies, rRT-PCR results have been variable due to pre-test the serum antibody levels between acute and convalescent specimens 15 . We strongly believe that a similar diagnostic approach is necessary for a largely unknown entity such as COVID-19, 294 perhaps with a short duration between specimens collected, as demonstrated in this study.

High specificity testing is crucial in low-prevalence settings, as shown in our data; the 296 ELISA test we employed had 100% specificity with a negative predictive value of 100%. We 297 evaluated 6000+ serum and nasopharyngeal swabs from pre-procedure patients and found that 298 the positivity rate was significantly higher by serological test than rRT-PCR. These pre-299 procedure patients were asymptomatic and represented a true random sample from the central 300 Texas region. We observed 5.5% sero-prevalence in this region. Serological tests thus have a 301 significant role in downstream clinical decision-making (use of enhanced PPE or rescheduling) 302 and patient triaging to appropriate care and/or discharge.

The intent of this study was not to provide any guidelines or recommendations on how to 304 use anti-SARS-CoV-2 serological tests in various settings, especially since the CDC recommends 305 that serological tests alone should not be used for diagnosis. However, the CDC also 306 recommends that, in certain situations, serologic assays may be used, in conjunction with viral 307 detection tests, to support clinical assessment of persons who present late in their illnesses 3 . We 

ELISA method used in the study was verified for its specificity and non-specific binding as 385 described in the methods. Five discordant samples from outpatient specimens were serially 386 diluted and tested on the ELISA method. Specimen tested exhibited a linear decrease in the IgG 387 concentration and percent recovery of the analyte is shown below in the data table. Using outpatient data and ROC analysis an assay cutoff of 13 AU/mL was calculated. ROC was 391 determined using EP evaluator software. Residual serum specimens were available for 9 in-patients who were followed-up for serum IgG 395 titers over the period of their hospital stay. Serum IgG titers were determined using ELISA 396 method as described in the methods and AU/mL is plotted against the time. Data presented in the 397 table represents actual titers for specific patients vs. time. 398  Table 1A : Comparison of rtRT-PCR and serum IgG using a lower (13 AU/mL) cut off Serological data collected from outpatient specimens were compared with rRT-PCR results to determine assay performance characteristics. ROC analysis was performed to draw assay cutoff, data presented Table 1A and 1B show performance characteristics at different levels of assay cutoffs. 

World Health Organization. Coronavirus disease (COVID-19) pandemic

Clinical course and risk factors for mortality of adult inpatients

Authors sincerely thank Jeffry Hunt for help with data extraction, Courtney Shaver

Data shown in the above tables represent specimens concurrently collected from ED patients. Specimens were tested for serum IgG and SARS-CoV-2 RNA as described in the methods. Electronic health records were reviewed for symptoms of COVID-19 as per CDC criteria and corresponding test results were noted for diagnosis of SARS-CoV-2 infection in the ED cohort.